As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
CRA Insights: Blockchain & Crypto
Blockchain technologies are disrupting established industries as well as creating new ones. CRA’s experts bring the rigor of their expertise and credentials to...